Organogenesis Holdings Inc. (ORGO) Income Statement
ORGO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsORGO revenue and net income
Where ORGO's revenue goes
2025Each bar shows an amount and its share of revenue. ORGO kept 6.6% of revenue as net income.
ORGO profit margins
ORGO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +16.8% | +7.7% | +10.7% | +19.0% |
| Gross profit | +16.2% | +7.2% | +11.1% | +23.3% |
| Operating income | — | +35.8% | +15.9% | — |
| Net income | +4,201.0% | +33.6% | +16.5% | — |
| EPS (diluted) | +45.0% | +17.2% | +17.4% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ORGO quarterly EPS vs estimates
Organogenesis beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.17).
ORGO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $563.0M | $482.0M | $433.1M | $450.9M | $467.4M | $338.3M | $261.0M | $193.4M | $0 | $0 |
| Cost of revenue | $137.5M | $115.7M | $106.5M | $105.0M | $114.2M | $87.3M | $75.9M | $68.8M | $4.6M | $208,698 |
| Gross profit | $425.5M | $366.3M | $326.7M | $345.9M | $353.2M | $251.0M | $185.0M | $124.6M | −$4.6M | −$208,698 |
| Research & development | $44.5M | $50.3M | $44.4M | $39.8M | $30.7M | $20.1M | $14.8M | $10.7M | $9.1M | $6.3M |
| Sales, general & admin | $326.2M | $294.5M | $269.8M | $283.8M | $250.2M | $203.5M | $199.7M | $162.0M | $4.6M | $208,700 |
| Total operating expenses | $369.6M | $367.6M | $314.1M | $323.6M | $280.9M | $224.3M | $214.9M | $172.7M | $204.0M | $208,698 |
| Operating income | $55.9M | −$1.3M | $12.5M | $22.3M | $72.2M | $26.7M | −$29.9M | −$51.6M | −$4.6M | $208,698 |
| Interest income | $2.3M | — | — | — | — | — | $9.0M | $64,000 | $2.5M | — |
| Interest expense | $2.3M | $1.5M | $2.2M | $2.0M | $7.2M | $11.3M | $9.0M | $10.9M | $2.5M | $5.6M |
| Income before taxes | $47.0M | −$2.8M | $10.4M | $20.3M | $63.1M | $17.8M | −$38.6M | −$64.7M | −$2.1M | −$208,698 |
| Income taxes | $9.9M | −$3.7M | $5.4M | $4.8M | −$31.1M | $530,000 | $150,000 | $84,000 | −$7.0M | −$440,212 |
| Net income | $37.0M | $861,000 | $4.9M | $15.5M | $94.2M | $17.2M | −$38.7M | −$64.8M | −$2.1M | −$208,698 |
| EBITDA | $73.9M | $15.8M | $36.0M | $40.3M | $87.0M | $37.2M | −$19.7M | −$46.9M | −$4.6M | $7.1M |
| EPS (diluted) | $0.29 | $0.20 | $0.08 | $0.18 | $0.73 | $0.13 | −$0.42 | $0.41 | −$0.45 | −$0.02 |
| Gross margin | 75.6% | 76.0% | 75.4% | 76.7% | 75.6% | 74.2% | 70.9% | 64.4% | — | — |
| Operating margin | 9.9% | −0.3% | 2.9% | 4.9% | 15.5% | 7.9% | −11.4% | −26.7% | — | — |
| Net margin | 6.6% | 0.2% | 1.1% | 3.4% | 20.2% | 5.1% | −14.8% | −33.5% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $43.8M | $37.2M | $225.1M | $150.5M | $100.8M | $86.7M | $126.7M | $115.2M | $130.2M | $110.0M | $99.7M | $108.5M |
| Cost of revenue | $23.7M | $38.1M | $49.9M | $36.3M | $27.6M | $23.7M | $31.1M | $26.8M | $29.2M | $28.7M | $27.8M | $25.8M |
| Gross profit | $20.1M | −$913,999 | $175.2M | $114.2M | $73.1M | $63.0M | $95.6M | $88.4M | $101.0M | $81.3M | $71.9M | $82.7M |
| Research & development | $18.3M | $15.2M | $10.3M | $13.2M | $10.4M | $10.6M | $11.5M | $10.3M | $15.6M | $12.8M | $11.8M | $10.5M |
| Sales, general & admin | $54.0M | $65.2M | $100.2M | $79.7M | $73.8M | $72.5M | $73.9M | $71.8M | $76.5M | $72.3M | $53.1M | $64.2M |
| Total operating expenses | $71.1M | $64.1M | $109.9M | $92.6M | $84.0M | $83.1M | $85.4M | $82.1M | $114.9M | $85.1M | $73.2M | $74.7M |
| Operating income | −$51.0M | −$65.0M | $65.2M | $21.6M | −$10.8M | −$20.2M | $10.2M | $6.2M | −$13.9M | −$3.9M | −$1.3M | $8.1M |
| Interest income | $138,000 | $380,000 | — | $415,000 | $669,000 | $961,000 | — | — | — | — | — | — |
| Interest expense | — | — | $236,000 | $415,000 | $669,000 | $961,000 | $61,000 | $471,000 | $620,000 | $514,000 | $502,000 | $444,000 |
| Income before taxes | −$50.9M | −$68.5M | $63.4M | $21.2M | −$11.8M | −$25.8M | $10.3M | $5.8M | −$14.5M | −$4.3M | −$1.8M | $7.6M |
| Income taxes | $45.4M | −$12.3M | $19.7M | −$407,000 | −$2.4M | −$6.9M | $2.6M | −$6.5M | $2.5M | −$2.2M | −$1.2M | $4.5M |
| Net income | −$99.3M | −$56.2M | $43.7M | $21.6M | −$9.4M | −$18.8M | $7.7M | $12.3M | −$17.0M | −$2.1M | −$568,000 | $3.2M |
| EBITDA | −$44.3M | −$56.1M | $70.4M | $28.1M | −$5.2M | −$19.5M | $16.6M | $10.7M | −$9.7M | $144,000 | $11.0M | $11.9M |
| EPS (diluted) | −$0.71 | −$0.34 | $0.31 | $0.18 | −$0.09 | −$0.11 | $0.07 | $0.10 | $0.04 | −$0.01 | −$0.00 | $0.04 |
| Gross margin | 45.9% | −2.5% | 77.8% | 75.9% | 72.6% | 72.6% | 75.5% | 76.7% | 77.6% | 73.9% | 72.1% | 76.2% |
| Operating margin | −116.5% | −174.7% | 29.0% | 14.4% | −10.7% | −23.3% | 8.1% | 5.4% | −10.7% | −3.5% | −1.3% | 7.4% |
| Net margin | −227.0% | −150.9% | 19.4% | 14.3% | −9.3% | −21.7% | 6.1% | 10.7% | −13.1% | −1.9% | −0.6% | 2.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ORGO's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ORGO financial results
In fiscal year 2025 (ended December 31, 2025), Organogenesis reported revenue of $563.0 million, up 16.8% from the year before. It had net income of $37.0 million (up 4,201.0%), a net profit margin of 6.6%. Diluted earnings per share came to $0.29. Over five years revenue grew at an average rate of 10.7% a year.
See the ORGO stock overview for the latest quote and news, or the ORGO chart for price history and technical indicators.
ORGO income statement FAQ
What is Organogenesis's annual revenue?
Organogenesis reported total revenue of $563.0 million for fiscal year 2025, which ended on December 31, 2025. That was up 16.8% from $482.0 million the previous year.
Is Organogenesis profitable?
Yes. Organogenesis reported net income of $37.0 million in fiscal 2025, a net profit margin of 6.6%; its operating margin was 9.9%.
What is Organogenesis's gross margin?
Organogenesis's gross margin was 75.6% in fiscal 2025: for every $100 of revenue, Organogenesis kept $76 after the direct cost of its products and services.
How much does Organogenesis spend on research and development?
Organogenesis spent $44.5 million on research and development in fiscal 2025, 7.9% of revenue.
How fast is Organogenesis growing?
Revenue grew 10.7% a year on average over the last five fiscal years, from $338.3 million to $563.0 million.
What are Organogenesis's earnings per share?
Organogenesis earned $0.29 per diluted share in fiscal 2025, compared with $0.20 a year earlier.
When will Organogenesis report its next earnings?
Organogenesis is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Organogenesis's fiscal year end?
Organogenesis's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.